The Bio Pharmaceutical Society of Korea Announces the 5th Korea-Japan Joint Pharmaceutical Symposium
In an effort to support the growth and collaboration of the biopharmaceutical industries in Korea and Japan, the Bio Pharmaceutical Society of Korea, led by Chairman Noh Yeon-hong, has announced the upcoming ‘5th Korea-Japan Joint Pharmaceutical Symposium’. The event, organized by both associations, will be held on September 4 at COEX in Gangnam-gu, Seoul, and will mark the resumption of the symposium after a four-year hiatus due to the COVID-19 pandemic.
Over the years, the two associations have established a tradition of hosting joint seminars to foster the joint development of their respective biopharmaceutical industries and to facilitate access to the pharmaceutical market. Since 2016, the symposium has expanded to include participation from the Ministry of Food and Drug Safety of Korea, the Ministry of Health, Labor and Welfare of Japan, and the General Organization for Pharmaceuticals and Medical Devices.
During the symposium, regulatory authorities from both countries will play an active role as sponsors. The event will feature various topics pertinent to the pharmaceutical industry, including the latest regulatory policy trends, plans to promote industrial innovation through regulatory improvement, strategies to strengthen the supply chain of raw materials, and initiatives to enhance health insurance coverage.
Key Discussions and Presentations
The event will witness enlightening presentations from Ahn Young-jin, head of the drug policy department at the Ministry of Food and Drug Safety, and Naoyuki Yasuda, deputy secretary general of the Japan Pharmaceutical and Medical Devices Agency. These distinguished speakers will share insights into the COVID-19 response policies of their respective countries, e-labeling, and management systems related to clinical trials.
Moreover, a session focused on promoting regulations for innovation in the pharmaceutical industry will delve into topics such as regulatory harmonization and bilateral cooperation in pharmaceutical manufacturing and quality control standards. Esteemed speakers, including Kim Chun-rae, Director of Pharmaceutical Quality Division at the Ministry of Food and Drug Safety, and Daisuke Tanaka, Director General of International Programs at the Japan Institute of Medical and Pharmaceutical Devices, will provide valuable perspectives on this subject.
Another significant theme to be explored during the symposium is the utilization of real clinical data and evidence. Renowned experts, such as Professor Shin Ju-yeong from Sungkyunkwan University College of Pharmacy and Daisuke Koga, General Secretary RA Global at the Japanese Pharmaceuticals Comprehensive Organization of Medical Devices, will present case studies and discuss the regulatory aspects of applying these methodologies in the pharmaceutical field.
Exploring Industry Trends and Drug Prices
Furthermore, a dedicated session will tackle industry trends, drug prices, and ways to enhance the supply chain of raw materials and pharmaceuticals. Distinguished speakers, including Park No-Jun, Managing Director of Hwail Pharmaceuticals, and Ichiko Fujikawa, Chairman of the Japan Pharmaceutical Import and Export Association, will shed light on measures to ensure sustainable supply chains.
The symposium will also address the proper management of insurance drugs’ health and Japan’s drug pricing system. Noteworthy experts, including Chang-Hyun Oh, Pharmaceutical Division Manager at the Ministry of Health Insurance and Welfare, and Katsuya Sawadaishi, Deputy Director of the Office of Policy Planning and Medical Information Management Promotion at Japan’s Ministry of Health, Labor and Welfare, will share their insights on these topics.
Fostering Dialogue between Industry Panels
In addition, industry panels from both countries will engage in a public-private panel discussion focused on balancing health insurance financial management and recognizing the value of new drugs. Professor Lee Jong-hyeok from the College of Pharmacy at Chung-Ang University will moderate the discussion, which will feature esteemed participants such as Oh Chang-hyun from the Ministry of Health and Welfare, Katsuya Sawdaishi from the Ministry of Health, Labor and Welfare in Japan, Kang Hee-seong, CEO of Daewoong Pharmaceutical, and Koyama Tatsuya, leader of the Korean team of the Japan Pharmaceutical Association.
Chairman Roh Yeon-hong of the Bio Pharmaceutical Society of Korea emphasized the significance of this symposium as an essential platform for sharing updates on major pharmaceutical systems in both countries post-COVID-19. He believes that this event will serve as a foundation for collaboration and development between regulatory authorities and the industry.
For those interested in attending, applications for the symposium can be made on a first-come, first-served basis. Member companies of the association can register for free on the Korea Pharmaceutical Bio Association website.
The Bio Pharmaceutical Society of Korea (Chairman Noh Yeon-hong) announced on the 17th that the Pharmaceutical Society of Japan (Chairman Hiroaki Ueno) will hold the ‘5th Korea-Japan Joint Pharmaceutical Symposium’ on September 4 at COEX, Gangnam-gu, Seoul.
The two associations have regularly held joint seminars to support the joint development of the two countries’ biopharmaceutical industry and access to the pharmaceutical market. In particular, since 2016, the Ministry of Food and Drug Safety of Korea, the Ministry of Health, Labor and Welfare of Japan, and the General Organization for Pharmaceuticals and Medical Devices have participated, expanding the scale to a joint public symposium- private which includes medicines and medical devices.
This symposium, an offline event that resumed after 4 years since 2019 due to COVID-19, is hosted by associations from both countries, and regulatory authorities from both countries are participating as sponsors. The topics of the symposium included △ the latest regulatory policy trends for pharmaceuticals in both countries △ a plan to promote industrial innovation through regulatory improvement △ a plan to strengthen the supply chain of raw materials and △ a plan to strengthen health insurance coverage.
At this event, Ahn Young-jin, head of the drug policy department at the Ministry of Food and Drug Safety, and Naoyuki Yasuda, deputy secretary general of the Japan Pharmaceutical and Medical Devices Agency, will present the two countries’ COVID-. 19 response policies, e-labeling, and management systems related to classified clinical trials. Later, in the session on measures to promote regulation for innovation in the pharmaceutical industry of the two countries, on the theme of regulatory harmonization △ regulatory harmonization and bilateral cooperation in the field of pharmaceutical manufacturing and quality control standards (GMP) (Kim Chun-rae , Director of Pharmaceutical Quality Division, Ministry of Food and Drug Safety) △Innovation and regulation of pharmaceutical regulatory policy A plan to strengthen harmonization (Daisuke Tanaka, Director General of International Programs, Japan Institute of Medical and Pharmaceutical Devices) is to be announced. Then, with the theme of real clinical data (RWD) and real clinical evidence (RWE) △ New drug approval and indication expansion using an external control group (Professor Shin Ju-yeong, Sungkyunkwan University College of Pharmacy) △ RWD/RWE use cases regulate pharmaceuticals (Daisuke Koga Japanese Pharmaceuticals Comprehensive Organization of Medical Devices General Secretary RA Global) is held.
In the industry trend and drug prices session, an opportunity was given to identify ways to strengthen the supply chain of raw materials and pharmaceuticals in both countries and to strengthen health insurance coverage. △ Measures to ensure a sustainable API supply chain in Korea (Park No-Jun, Managing Director of Hwail Pharmaceuticals) △ Measures to ensure a stable supply of APIs imported from Japan (Ichiko Fujikawa, Chairman of Japan Pharmaceutical Import and Export Association) △ Proper management of insurance drugs health (Chang-Hyun Oh, Ministry of Health Insurance and Welfare) Pharmaceutical Division Manager) ▲ Trends in Japan’s drug pricing system (Katsuya Sawadaishi, Deputy Director, Office of Policy Planning Policy and Medical Information Management Promotion of the Medical and Medical Industry, Japan’s Ministry of Health, Labor and Welfare), etc. will follow.
In addition, industry panels from both countries will hold a public-private panel discussion on the topic of balancing health insurance financial management and new drug value recognition policies to promote new drug development. Professor Lee Jong-hyeok from the College of Pharmacy at Chung-Ang University will chair the event, and Oh Chang-hyun, head of the Ministry of Health and Welfare, Katsuya Sawdaishi, deputy director of the Ministry of Health, Labor and Welfare. Japan, Kang Hee-seong, head of Daewoong Pharmaceutical, and Koyama Tatsuya, leader of the Korean team of the Japan Pharmaceutical Association will participate.
Roh Yeon-hong, chairman of the Bio Pharmaceutical Society of Korea, said, “This symposium will be an important opportunity to share the changes and directions of major pharmaceutical systems in the two countries after the COVID-19 pandemic, and to lay the foundation for development. between regulators and the industry.”
Meanwhile, applications for this symposium will be closed on a first-come, first-served basis, and member companies of the association can register for free on the Korea Pharmaceutical Bio Association website publication.
Poster for the 5th Korea-Japan Joint Pharmaceutical Symposium / Graphic = Korea Bio Pharmaceutical Society
#5th #KoreaJapan #Joint #Pharmaceutical #Symposium #held #Sharing #regulations #drug #price #trends
